Cargando…

Rewiring cancer cell death to enhance oncolytic viro-immunotherapy

Oncolytic viruses are novel immunotherapeutic agents that appear to mediate potent antineoplastic effects in both preclinical and clinical settings. Recent studies demonstrate that manipulating the mechanisms whereby cancer cells die in the course of oncolytic virotherapy has potential to boost anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Workenhe, Samuel T, Mossman, Karen L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912054/ https://www.ncbi.nlm.nih.gov/pubmed/24498567 http://dx.doi.org/10.4161/onci.27138

Ejemplares similares

Immunogenic cell death: The cornerstone of oncolytic viro-immunotherapy
por: Palanivelu, Lalitha, et al.
Publicado: (2023)

Live vaccines—a short‐cut to cancer viro‐immunotherapy
por: Wirth, Thomas C, et al.
Publicado: (2019)

Oncolytic Viro-Immunotherapy: An Emerging Option in the Treatment of Gliomas
por: Zeng, Jiayi, et al.
Publicado: (2021)

Serum HMGB1 is a predictive and prognostic biomarker for oncolytic immunotherapy
por: Liikanen, Ilkka, et al.
Publicado: (2015)

Pre-surgical oncolytic virotherapy improves breast cancer outcomes
por: Mullins-Dansereau, Victor, et al.
Publicado: (2019)

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
por: Bommareddy, Praveen K., et al.
Publicado: (2019)

Chemokine-enhanced DNA vaccination in cancer immunotherapy
por: Igoucheva, Olga, et al.
Publicado: (2013)

Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a “Hammer” and “Anvil”
por: Melzer, Michael Karl, et al.
Publicado: (2017)

A novel strategy for modulation of MDSC to enhance cancer immunotherapy
por: Ghansah, Tomar
Publicado: (2012)

Oncolytic adenoviruses: A potent form of tumor immunovirotherapy
por: Cerullo, Vincenzo, et al.
Publicado: (2012)

Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells
por: Fonteneau, Jean-François, et al.
Publicado: (2013)

A combination of genetically engineered oncolytic virus and melittin-CpG for cancer viro-chemo-immunotherapy
por: Bahreyni, Amirhossein, et al.
Publicado: (2023)

Dendritic cell-based immunotherapy in ovarian cancer
por: Coosemans, An, et al.
Publicado: (2013)

Cancer cell associated glycans as targets for immunotherapy
por: Vankemmelbeke, Mireille, et al.
Publicado: (2015)

Myeloid-derived suppressor cells as a Trojan horse: A cellular vehicle for the delivery of oncolytic viruses
por: Pan, Ping-Ying, et al.
Publicado: (2013)

Cancer immunotherapy with exosomes requires B-cell activation
por: Näslund, Tanja I, et al.
Publicado: (2013)

New insights into the role of NK cells in cancer immunotherapy
por: Salagianni, Maria, et al.
Publicado: (2012)

Targeting dendritic cells in situ for breast cancer immunotherapy
por: Wang, Bei
Publicado: (2012)

Cancer immunotherapy: Benefit and harm?
por: Characiejus, Dainius
Publicado: (2012)

Metabolic rewiring in cancer-associated fibroblasts provides a niche for oncogenesis and metastatic dissemination
por: Liu, Jingyi, et al.
Publicado: (2015)

Two is better than one: Complementing oncolytic virotherapy with gemcitabine to potentiate antitumor immune responses
por: Gujar, Shashi A, et al.
Publicado: (2014)

Discovering cancer immunotherapy targets in vivo
por: Zhou, Penghui, et al.
Publicado: (2014)

Toward the next generation of NK cell-based adoptive cancer immunotherapy
por: Ni, Jing, et al.
Publicado: (2013)

Extracellular Vesicles-Mimetic Encapsulation Improves Oncolytic Viro-Immunotherapy in Tumors With Low Coxsackie and Adenovirus Receptor
por: Zhang, Yonghui, et al.
Publicado: (2020)

Combining conventional chemotherapy and γδ T cell-based immunotherapy to target cancer-initiating cells
por: Todaro, Matilde, et al.
Publicado: (2013)

Targeting cancer stem cells with ALDH1A1-based immunotherapy
por: DeLeo, Albert B.
Publicado: (2012)

Radiation and immunotherapy: Renewed allies in the war on cancer
por: Seung, Steven K., et al.
Publicado: (2012)

Pharmacological DNA demethylation: Implications for cancer immunotherapy
por: Roulois, David, et al.
Publicado: (2015)

Targeting the right regulatory T-cell population for tumor immunotherapy
por: Weiss, Vivian L., et al.
Publicado: (2012)

Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens
por: Gameiro, Sofia R, et al.
Publicado: (2014)

Specificity may be overrated in cancer immunotherapy: Getting to know the nonspecific side of memory T Cells
por: Sckisel, Gail D., et al.
Publicado: (2012)

FIST, a sword and shield fusokine for cancer immunotherapy
por: Penafuerte, Claudia, et al.
Publicado: (2012)

Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies
por: Abate-Daga, Daniel, et al.
Publicado: (2014)

The immune landscape of human tumors: Implications for cancer immunotherapy
por: Bindea, Gabriela, et al.
Publicado: (2014)

Multifunctional γδ T cells and their receptors for targeted anticancer immunotherapy
por: Scheper, Wouter, et al.
Publicado: (2013)

Immunotherapy of acute myeloid leukemia based on γδ T cells
por: Gertner-Dardenne, Julie, et al.
Publicado: (2012)

Immunotherapy of HPV-associated head and neck cancer: Critical parameters
por: Nizard, Mevyn, et al.
Publicado: (2013)

Engineering Grp170-based immune modulators for cancer immunotherapy
por: Yu, Xiaofei, et al.
Publicado: (2013)

IL-21 in cancer immunotherapy: At the right place at the right time
por: Santegoets, Saskia JAM, et al.
Publicado: (2013)

Of microspheres and microbes: A double-hit strategy for cancer immunotherapy
por: Brinkhoff, Benjamin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_0j235odqh1o84arskgaicp4evg